HCPCS Q5106: Epoetin alfa-epbx (Retacrit) 1000-unit Injection

HCPCS Level II code Q5106 represents injection of epoetin alfa-epbx (Retacrit), a biosimilar erythropoiesis-stimulating agent (ESA), in 1000-unit increments. ESAs play a central role in treating anemia related to chronic conditions and certain therapies, making this code relevant across outpatient and ambulatory care settings where injectable biologics are administered. Nationally, utilization and coverage of biosimilar ESAs affect drug spend, patient access, and contracting strategies for major payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for epoetin alfa-epbx, benchmarks for unit-based billing, common sites of service, and payer coverage patterns. The publication summarizes typical billing practices, relevant policy considerations for biosimilars, and coding nuances specific to HCPCS Level II code Q5106.

The report helps payers, providers, and billing professionals understand where Q5106 fits within ESA therapy workflows, what to expect in outpatient administration settings, and which commercial and federal payers are commonly involved. Data not available in the input is noted where applicable.

Billing Code Overview

HCPCS Level II code Q5106 describes an injection of epoetin alfa-epbx (Retacrit), biosimilar, provided in a unit dose of 1000 units. This product is an erythropoiesis-stimulating agent (ESA) used to treat anemia by stimulating red blood cell production.

Service type: Drug administration — therapeutic injectable (erythropoiesis-stimulating agent)

Typical site of service: Outpatient clinics, physician offices, and other ambulatory settings where injectable biologics are administered

Clinical Context

A 68-year-old female with chemotherapy-induced anemia secondary to metastatic breast cancer presents to the oncology infusion center for outpatient management of symptomatic anemia. Her hemoglobin is 8.6 g/dL and the oncology team elects to administer an erythropoiesis-stimulating agent to reduce transfusion needs and improve quality of life. The service provided is Q5106 — injection of epoetin alfa-epbx (Retacrit) 1000 units — administered subcutaneously in the clinic. The clinical workflow includes order entry by the oncologist, pharmacist verification of dose and formulary/biosimilar selection, nursing preparation and counseling, administration with documentation of lot number and expiration, observation for immediate adverse events, and billing to the patient’s medical benefit using appropriate modifiers and diagnosis linkage for chemotherapy-induced anemia (or other approved non-ESRD indications). Typical site of service is an outpatient infusion center, oncology clinic, or physician office that manages supportive oncology therapies. Supplies, injection administration, and patient education are documented in the medical record per payer requirements.

Coding Specifications

Modifier	Description	When to Use
`JZ`	No biologic product furnished (no drug or biological was supplied)	Rarely used; would not typically apply when `Q5106` drug is administered but relevant if billing only an administration service without product supply.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology & Oncology	Medical subspecialists who prescribe and oversee ESA therapy in cancer-related anemia.
`207Q00000X`	Medical Oncology	Physicians administering chemotherapy and supportive oncology medications in outpatient infusion centers.
`363L00000X`	Nurse Practitioner	Advanced practice providers who frequently order and administer supportive injections in clinic.
`163W00000X`	Registered Nurse	Clinic nurses who prepare and administer subcutaneous injections and document administration.
`207L00000X`	Hematology	Specialists managing anemia of chronic disease and coordinating ESA therapy.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D63.0`	Anemia in neoplastic disease	Primary indication for epoetin alfa in oncology patients to treat chemotherapy-induced anemia and reduce transfusion needs.
`D64.9`	Anemia, unspecified	Used when anemia is present but specific cause not yet documented; may be used temporarily when prescribing ESA.
`D50.9`	Iron deficiency anemia, unspecified	ESA therapy is sometimes considered if iron repletion is inadequate or concurrent iron deficiency has been addressed.
`N18.9`	Chronic kidney disease, unspecified	While `Q5106` is for non-ESRD use, CKD-related anemia may be a non-ESRD indication in earlier stages.
`D61.9`	Aplastic anemia, unspecified	Less common indication; included when marrow failure contributes to anemia requiring specialized management and hematology oversight.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Commonly billed for the act of administering `Q5106` when the payer requires a separate administration code in addition to the drug HCPCS.
`90772`	Therapeutic, prophylactic, or diagnostic injection administration with monitoring for adverse effects; subcutaneous or intramuscular (add-on)	Used by some practices to report additional monitoring time or when payer policy supports separate administration codes with monitoring.
`36415`	Collection of venous blood by venipuncture	Performed before or during the visit to obtain hemoglobin and laboratory monitoring needed to authorize ESA dosing.
`99070`	Supplies and materials (except spectacles), non-covered items or services, used during the visit	May be used to bill for non-bundled supplies if payer allows separate reporting.
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Relevant when epoetin therapy is provided as part of a longer infusion-based visit or when IV access and infusion services are part of the encounter.

OpenPayer

Summary & Overview